Success Metrics

Clinical Success Rate
30.0%

Based on 3 completed trials

Completion Rate
30%(3/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
7(64%)

Phase Distribution

Ph phase_2
1
9%
Ph phase_1
5
45%
Ph phase_3
5
45%

Phase Distribution

5

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
5(45.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

27.3%

3 of 11 finished

Non-Completion Rate

72.7%

8 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(3)
Terminated(8)

Detailed Status

Terminated7
Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
30.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (45.5%)
Phase 21 (9.1%)
Phase 35 (45.5%)

Trials by Status

completed327%
terminated764%
withdrawn19%

Recent Activity

0 active trials
Showing 5 of 11
withdrawnphase_1

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NCT00820794
terminatedphase_3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00658372
terminatedphase_3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

NCT00658762
terminatedphase_3

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

NCT00735267
terminatedphase_3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00820794Phase 1

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

Withdrawn
NCT00658372Phase 3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

Terminated
NCT00658762Phase 3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

Terminated
NCT00735267Phase 3

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

Terminated
NCT00658008Phase 3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

Terminated
NCT00542685Phase 3

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

Completed
NCT00921063Phase 2

A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

Completed
NCT00800280Phase 1

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Terminated
NCT00537615Phase 1

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Completed
NCT00809536Phase 1

Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time

Terminated
NCT00721422Phase 1

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11